Summary

Eligibility
for people ages 12-70 (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
study ends around

Description

Summary

Glanzmann thrombasthenia (GT) is a serious inherited bleeding disorder. In GT, platelets, the blood cells that normally stick together at the site of an injury to stop bleeding, are unable to properly do so. As a result, bleeding does not stop as it should. Bleeding in GT often starts without warning, can happen frequently, and can be severe. It most commonly affects the nose, mouth and gums, gastrointestinal tract, and skin, and many women and girls with GT experience heavy menstrual bleeding. Over time, bleeding can lead to iron deficiency and anemia. Some bleeding episodes require emergency care, hospitalization, transfusion, or surgery, and some can be life-threatening.

Sutacimig is an investigational medicine given as an injection under the skin (subcutaneous injection). It is designed to help platelets work at the site of bleeding despite the underlying defect in GT. It is intended to be given regularly to help prevent bleeding (prophylaxis), rather than only to treat bleeding after it starts.

The purpose of this study is to find out whether sutacimig, given as prophylaxis, reduces the number of treated bleeding episodes in people with GT compared with no prophylaxis, and to evaluate its safety and tolerability.

Official Title

SOLARA: A Phase 3 Study of the Efficacy and Safety of Sutacimig in Participants With Glanzmann Thrombasthenia

Keywords

Thrombasthenia, Glanzmann, Glanzmann Thrombasthenia, Bleeding, Glanzmann's thrombasthenia, GT, Inherited Platelet Function Disorder, Rare Bleeding Disorder, ITGA2B, ITGB3, GPIIb/IIIa, Sutacimig, HMB-001, Epistaxis, Iron Deficiency Anemia, Blood Coagulation Disorders, Inherited Blood Coagulation Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, Blood Platelet Disorders, Hemorrhagic Disorders, Genetic Diseases, Inborn, Congenital Hereditary, Neonatal Diseases and Abnormalities, Hemorrhage, Iron-Deficiency Anemia, Inborn Genetic Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Eligibility

You can join if…

Open to people ages 12-70

  • Has the ability to provide informed consent to participate in the clinical study before completing any study-related procedures, and has an understanding, ability, and willingness to comply with clinical study procedures and restrictions.
  • Adults 18 to 70 years.
  • Adolescents 12 to <18 years, dependent on geographical location.
  • Has clinical bleeding phenotype consistent with Glanzmann thrombasthenia (GT) and documentation of either diagnostic laboratory criteria (a) or (b) below:
    1. Abnormal platelet aggregometry AND flow cytometry
    2. A confirmed genetic mutation in ITGA2B or ITGB3.
  • Participants have experienced at least four treated bleeding events related to GT within the 12 months prior to Screening.

You CAN'T join if...

  • Prior exposure to sutacimig.
  • History of clinically significant hypersensitivity associated with monoclonal antibody therapies.
  • Congenital or acquired bleeding disorders other than GT.
  • Medical condition (other than GT) that constitutes an increased risk of having uncontrolled bleeding events during the study or other conditions per Investigator discretion.
  • History of venous or arterial thromboembolic (TE) event or TE disease except for catheter-associated vein thrombosis.
  • Co-existing thrombophilia disorder.

Locations

  • University of California Davis (UC Davis) Medical Center accepting new patients
    Sacramento California 95817 United States
  • University of California San Francisco (UCSF) Medical Center accepting new patients
    San Francisco California 94143 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Hemab ApS
ID
NCT07935356
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 76 study participants
Last Updated